Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lag Phase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Lag Phase. Displaying page 1 of 1.
    EudraCT Number: 2016-002213-21 Sponsor Protocol Number: VP-VEC-162-2102 Start Date*: 2016-08-15
    Sponsor Name:Vanda Pharmaceuticals Inc
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL PROOF OF CONCEPT STUDY TO EVALUATE THE EFFECTS OF MULTIPLE ORAL DOSES OF TASIMELTEON AND MATCHING PLACEBO IN TRAVELERS WITH JET...
    Medical condition: Jet Lag Disorder (JLD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003198-14 Sponsor Protocol Number: VP-VEC-162-3106 Start Date*: 2015-12-21
    Sponsor Name:Vanda Pharmaceuticals Inc
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of multiple oral doses of tasimelteon and matching placebo in travelers with Jet L...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002660-41 Sponsor Protocol Number: NVG14L127 Start Date*: 2019-04-29
    Sponsor Name:SANTEN SAS
    Full Title: A Phase IIIb, prospective, interventional, multicentre, three-year study to explore the long-term evolution of sign and symptoms, and occurrence of complications in Dry Eye Disease patients with se...
    Medical condition: DRY EYE DISEASE WITH SEVERE KERATITIS
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10023332 Keratitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2005-004378-25 Sponsor Protocol Number: PC SOR-101 Start Date*: 2005-12-14
    Sponsor Name:Urologische Klinik und Poliklinik, Klinikum Großhadern der LMU München
    Full Title: A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxe...
    Medical condition: Locally progressed and / or metastasized hormon refractory prostate carcinoma
    Disease: Version SOC Term Classification Code Term Level
    10001203
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-008175-34 Sponsor Protocol Number: MOT111809 Start Date*: 2009-03-31
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Single Doses of the Oral Motilin Receptor A...
    Medical condition: Diabetic Gastroparesis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051153 Diabetic gastroparesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003314-24 Sponsor Protocol Number: CC-10004-PPSO-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis in adolescents (ages 12 to 17 years, inclusive) and in children (ages 6 to 11 years, inclusive).
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002924-18 Sponsor Protocol Number: 1517-CL-1001 Start Date*: 2019-07-11
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase 1 Crossover Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet and Pediatric Azo Dye free Mini-tablet (Solid and Suspension)...
    Medical condition: Healthy Adult Volunteers (intended indication is anemia associated with chronic kidney disease (CKD))
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004009-37 Sponsor Protocol Number: MD2021.01 Start Date*: 2021-11-05
    Sponsor Name:Prothya Biosolutions BV
    Full Title: A Phase 1/2 study of the dose-response in pharmacodynamics and safety of prothrombin complex concentrate Cofact in healthy subjects under vitamin K antagonist anticoagulation
    Medical condition: Treatment of bleeding and perioperative prophylaxis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10005103 Bleeding LLT
    21.0 10042613 - Surgical and medical procedures 10036898 Prophylaxis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002208-15 Sponsor Protocol Number: 208132 Start Date*: 2019-03-04
    Sponsor Name:ViiV Healthcare UK Limited
    Full Title: A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Tre...
    Medical condition: Treatment of human immunodeficiency virus-1 (HIV-1)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004108-23 Sponsor Protocol Number: 17097AB-AS Start Date*: 2018-10-09
    Sponsor Name:Belfast Health and Social Care Trust
    Full Title: Low-dose atropine eye drops to reduce progression of myopia in children: a multi-centre placebo controlled randomised trial in the United Kingdom (CHAMP UK)
    Medical condition: Myopia
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002345-38 Sponsor Protocol Number: 12/0033/CTU/IMM/001 Start Date*: 2012-10-30
    Sponsor Name:University College London
    Full Title: A prospective randomised controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Medical condition: Patients with antiphospholipid syndrome (APS), with or without systemic lupus erythematosus (SLE).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10002817 Antiphospholipid syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003171-35 Sponsor Protocol Number: LanLyx Start Date*: 2013-09-19
    Sponsor Name:Profil Institut für Stoffwechselforschung GmbH
    Full Title: A bicentric open-label, randomized, two-parallel-group study investigating the impact of combined Lantus®(insulin glargine) and Lyxumia ®(lixisenatide) on insulin secretion and gastric emptying in ...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    16.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001775-41 Sponsor Protocol Number: UX023-CL304 Start Date*: 2015-12-16
    Sponsor Name:Ultragenyx Pharmaceutical Inc.
    Full Title: An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults with X-linked Hypophosphatemia (XLH)
    Medical condition: XLH is a disorder of hypophosphatemia, renal phosphate wasting, and the most common inheritable form of rickets. In XLH patients, excess circulating fibroblast growth factor (FGF23) impair phospha...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10016206 Familial hypophosphataemic rickets LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002318-11 Sponsor Protocol Number: 109MS306 Start Date*: 2014-06-05
    Sponsor Name:Biogen Idec Research Limited
    Full Title: Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) BE (Ongoing) IT (Ongoing) HU (Ongoing) DK (Completed) CZ (Ongoing) PL (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) FR (Ongoing) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001967-11 Sponsor Protocol Number: PBD01071 Start Date*: 2015-02-05
    Sponsor Name:Probiodrug AG
    Full Title: A Phase 2A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Trial of PQ912 in Subjects with early Alzheimer's Disease
    Medical condition: Early Stage Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    19.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FI (Completed) DE (Completed) SE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-001069-18 Sponsor Protocol Number: CA224-060 Start Date*: 2018-09-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-Line Treatment...
    Medical condition: Gastric or Gastroesophageal Junction Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NO (Completed) BE (Completed) PL (Completed) AT (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000748-16 Sponsor Protocol Number: MT-2-01 Start Date*: 2017-09-14
    Sponsor Name:Minoryx Therapeutics S.L.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, MULTICENTER STUDY WITH OPEN-LABEL TREATMENT EXTENSION TO ASSESS THE EFFECT OF MIN-102 ON THE PROGRESSION OF ADRENOMYELONEUROPATHY IN M...
    Medical condition: ADRENOMYELONEUROPATHY IN MALE PATIENTS WITH X-LINKED ADRENOLEUKODYSTROPHY
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) HU (Ongoing) ES (Ongoing) NL (Ongoing) PL (Prematurely Ended) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022726-33 Sponsor Protocol Number: 251001 Start Date*: 2011-03-24
    Sponsor Name:Baxter Innovations GmbH
    Full Title: BAX326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1- 2%) Hemo...
    Medical condition: Previously treated patients (PTPs) with severe (FIX level < 1%) or moderately severe (FIX level 1- 2%) hemophilia B.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed) CZ (Completed) GB (Completed) DE (Prematurely Ended) SE (Completed) PL (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA